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Abstract: Background: The potential utility of microRNAs (miRNAs) in the diagnosis, prognosis, and
treatment of multiple disease states has been an area of great interest since their discovery. In patients
with cardiovascular disease, there is a large pool of literature amassed from the last decade assessing
their diagnostic and prognostic potential. This systematic review sought to determine whether existing
literature supports the use of miRNAs as prognostic markers after an Acute Coronary Syndrome (ACS)
presentation. Methods: A systematic review of published articles from 2005–2019 using MEDLINE
and EMBASE databases was undertaken independently by two reviewers. Studies addressing
prognosis in an ACS population yielded 32 studies and 2 systematic reviews. Results/conclusion:
23 prospective studies reported significant differences in miRNA levels and 16 compared the predictive
power of miRNAs. The most common miRNAs assessed included miR-133a, -208b, -21, -1, -34a,
-150, and -423, shown to be involved in cell differentiation, apoptosis, and angiogenesis. Barriers
to the use of miRNAs as prognostic markers include bias in miRNA selection, small sample size,
variable normalization of data, and adjustment for confounders. Therefore, findings from this
systematic review do not support the use of miRNAs for prognostication post-ACS beyond traditional
cardiovascular risk factors, existing risk scores, and stratifications tools.
Keywords: miRNA; biomarker; prognosis; acute coronary syndrome
1. Introduction
Coronary artery disease (CAD) is the leading cause of mortality worldwide [1]. Advancements
in early diagnosis and prognostication would allow for better risk stratification in an aging global
population. Since the discovery of miRNAs, there has been great interest in their role in various disease
processes, including atherosclerosis. As noncoding RNAs regulate posttranscription gene expression,
the potential of miRNAs as a biomarker or as a mediator of the disease process has been identified [2].
This has yielded a multitude of studies in miRNA level characterisation and its various potential
applications including diagnosis [3] and prognosis [4–6] in CAD.
Despite the large volume of existing literature on miRNAs in atherosclerosis, the vision of miRNA
panels being used in clinical practice to quickly and accurately diagnose CAD has not become a
reality. The availability of high-sensitivity cardiac Troponin T(hs-cTnT) allowing for early diagnosis
of myocardial infarction (MI) makes it increasingly difficult for potential or novel biomarkers to
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compete with those utilized in current practice [7]. Furthermore, contradictory results, variations in
methodology, and an abundance of underpowered studies have not facilitated inclusion of miRNAs in
current diagnostic and prognostic algorithms [8]. Amongst these limitations as well as technological
constraints, current large cohort studies, reviews [3], or meta-analyses [8] have similarly been unable to
demonstrate the value of miRNAs in a clinical diagnostic setting over traditional biomarkers, although
there is some suggestion they may be additive in diagnosis [9].
Nonetheless, cancer research has witnessed significant discoveries in identifying miRNAs as
potential cancer biomarkers or treatment targets. Thus, interest in identifying miRNAs through
discovery and validation of candidates that have diagnostic/prognostic potential is increasingly under
investigation in patients presenting with Acute Coronary Syndrome (ACS). As such, this review
discusses the current literature and outlines the need for further studies, with a particular focus on
identifying miRNAs post-ACS as prognostic biomarkers alongside traditional cardiovascular risk
factors, existing risk scores, and stratifications tools.
2. Materials and Methods
Electronic databases accessible via the University of Sydney: MEDLINE and EMBASE via Ovid
were used and supplemented by screening references of literature (via PubMed) deemed relevant to
the current study. The strategy of the literature search is summarised in Figure 1.
Figure 1. Flow diagram: prognostic utility of miRNAs in acute coronary syndrome—systematic
review [10]. ACS: acute coronary syndrome.
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A comprehensive search of the accessible published literature was conducted by combining
key search terms using the Boolean term AND and search term variations of microRNAs, coronary
artery disease/cardiovascular disease, and outcomes including morbidity/mortality using the Boolean
term OR as keywords to maximize sensitivity with the last search taking place on 27 August 2019.
The relevant MeSH (medical subject headings) terms or similar, available on MEDLINE and EMBASE,
were used to further cast a wider net and to maximise sensitivity of our search for relevant pieces of
literature. All records published up until August 2019 were included in our search, where the records
were either in English or an English translation was available.
However as only published studies in the public domain were accessed, this review is potentially
biased in favour of positive findings which are more often published and skewed towards findings
of significance for Caucasian populations given that most studies found involved predominantly
Caucasian patients. This review was undertaken by two reviewers J.B. and M.J., who conducted the
literature search and performed the data extraction of study characteristics and results (Table S1),
which could be a source of bias despite data extraction being conducted at 2 separate time points
and compared to minimise errors. Studies identified to be within the scope of the review were
assessed for bias within studies. Risk of bias was undertaken by 2 reviewers J.B and M.J. The QUIPS
(quality in prognosis studies) tool [11] was used to assess the quality of studies. The six main domains
included study participation, attrition, prognostic factor, outcome factor, confounding and statistical
analysis/reporting for determining the overall bias within each study and, thus, the value in this review.
Data was also collected to assess bias across studies on miRNA selection (Table S1).
There were initially 1127 articles identified (excluding ~630 duplicates automatically detected on
EndNote). Due to the choice of maximising sensitivity over specificity in the initial electronic search,
it then was necessary to determine inclusion and exclusion of literature by direct inspection of the
titles and abstracts to assess for relevance to the aims of this study.
Manual screening of the titles and abstract followed by full-text evaluation of the literature yielded
32 primary research articles/records (Figure 1) suitable for discussion within this review and two
meta-analysis. Articles were evaluated for relevance to the research question, where studies not
addressing the prognostic potential of miRNAs in the context of acute coronary syndromes, in vitro
studies, and those containing nonhuman populations were excluded. Details such as the population,
methods, findings, and limitations of the remaining records were catalogued (Table S1) for further
discussion. Authors followed the PRISMA guidelines for systematic review.
3. Results and Discussion
As briefly mentioned above, 32 primary research records were found to be relevant to the research
question (Table S1), and 2 recent systematic reviews with meta-analyses were found. Out of the studies,
29 were prospective and 3 were retrospective analyses (Figure 2) of patient populations. None of the
three retrospective studies were included in the reviews. Study sizes ranged from 30–1199 persons,
and follow-up times for the prospective populations ranged from 30 days to up to 6 years. Only 11
out of the 29 prospective studies deliberately recruited a healthy control population, only three of
which recruited matched controls [12–14]. As we discuss, it is important to note the study limitations
as outlined and detailed in Table S1 and factors including population size.
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Figure 2. Populations of original research studies in miRNA as biomarkers for prognosis in acute
coronary syndromes: Bar chart of original research articles included in this review, displaying patient
population in blue and control population in orange.
In general, studies investigated miRNA levels in serum or plasma, sampled as close to diagnosis
and treatment (percutaneous coronary intervention (PCI)) as relevant or up to 1 month after recruitment
except for one study measuring miRNA 6–36 months post ACS [15] and quantified using Real-Time
Polymerase Chain Reaction (RT-PCR). Outcomes analysed included but were not limited to all causes
and cardiac mortality, subsequent myocardial infarction, angina, heart failure, left-ventricular ejection
fraction, or contractility as a measure of function, arrhythmia, and hospitalisations.
Bias within studies was assessed using the QUIPS tool. Out of the 32 studies, 11 had low risk
of bias across the six domains assessed. High risk of bias was limited to abstracts only, likely as a
result of lack of reporting of domains in abstracts. Risk of bias in study confounding was common
amongst studies due to inadequate reporting of confounding factors or matching or to accounting for
confounders in analyses (Table S2).
In their assessment of the predictive power of miRNAs, some studies adjusted for potential
confounders such as age, gender, and preexisting cardiovascular (CV) risk factors such as smoking
status, the details of which were often unclear. Studies that considered the additional prognostic value
of miRNAs also performed adjustments for hs-TnT levels, creatinine kinase (CK), N-terminal pro
b-type Naturietic Peptide (NT-proBNP), and other traditional biomarkers.
There was significant diversity amongst studies in miRNA assessed. The most common miRNAs
included miR-133a, -208b, - 21, -1, -34a, -150, and -423. MiR-133, -1, and -208b have been shown to be
involved in angiogenesis, smooth muscle, and cardiomyocyte differentiation [3]. MiR-21 is upregulated
in cardiomyocytes and in fibroblasts. MiR-150 has been shown to be higher in patients without
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left ventricular remodeling [16], and MiR-423-5p is associated with congestive cardiac failure [17].
MiR-34a has been shown to be a p53-responsive miRNA [18] associated with cardiomyocyte apoptosis
(Figure S1).
In terms of individual studies, 23 prospective studies reported significant differences in miRNA
levels between the population, with recorded outcomes as listed above, and 16 compared the predictive
power of individual or panels of miRNAs. Of these, several utilised miRNA as risk predictors of CV
events or mortality post-ACS presentation. The miRNA reported in predictive modelling as biomarkers
of mortality in the ACS population included miR-122-5p, -328, -134, -208b, -140-3p, -210, -132, -19b,
-150, -145, -186, -499, -197, and -223. MiRNA reported as predictors of heart failure included miR-150,
-101, -16, -27, -328, -134, -208b, -34a, and -652. Methodology was similar across studies in predictive
modelling utilising Cox proportional hazard regression modelling, area under the receiver operating
characteristic curve (ROC), and Kaplan–Meier nonparametric survival analysis. Two earlier systematic
reviews assessed suggest limited clinical value to date given the diverse miRNAs investigated and
endpoints reported. Cao et al. [5] analysed 12 primary research articles and found that high levels
of expression of miRNAs were associated with shorter survival times. Kim et al. [6] investigated the
prognostic value of miRNA signatures in CAD patients and found miR-133a to be associated with
high mortality in CAD patients. Few miRNAs were studied across papers, but MiR-133a was one of
the most investigated cardiomyocyte-enriched miRNAs between studies. No studies found added
prognostic power of miR-133a when levels were compared to the predictive power of traditional
cardiovascular risk factors or troponin levels, although Kim et al. [6] reported that miR-133a may have
prognostic potential in pooled analysis. These findings are consistent with ours in demonstrating
limited prognostic value of miRNA, largely due to heterogeneity of miRNA assessed and significant
confounding limiting conclusive outcomes.
3.1. Potential Confounders
3.1.1. Sampling within Studies
Although some studies took multiple samples at various time points, it was often unclear as to
which samples were used for analysis. Pilbrow et al. [19] described changes in miRNA levels over
time. This study was notable as it explored effects of changes in medical treatment and storage time
of samples, which may result in miRNA degradation. However, a thorough investigation of these
potential confounders was largely unique to this study.
3.1.2. Sample Processing Variations
As found by Boeckel, et al. [20], heparin selectively increases the degradation of certain miRNAs
(miR-34a, miR-133a, miR-208, miR-378, and miR-499) within 10 minutes of administration and sustained
losses (miR-34a, miR-133a, and miR-208) 1 hour post-heparinisation. This phenomenon has only
been investigated in vascular and MI-related miRNA (miR-1, miR-17, miR-34a, miR-92a, miR-126,
miR-133a, miR-145, miR-208, miR-378, and miR-499) in blood. Similarly, Schulte et al. [9] showed that
heparin inhibits qPCR miRNA quantification, resulting in higher variation and reduced detectability
of miRNA. This was shown to be reversed using heparinase for miRNA 126-3p, 223-3p, and 150-5p in
a clinical AMI cohort. It was also noted that heparin suppressed Cel-miR-39, which was often used as
a normalisation control which may artificially elevate expression of reported miRNAs.
Many studies have avoided this issue by sampling blood prior to heparin administration, and some
collected samples into Ethylene Diamine Tetraacetic Acid (EDTA) tubes (e.g., Grabmaier et al. [12]).
However, most studies did not clearly specify how heparinisation was incorporated into their study
protocol. Glinge, et al. [21] found that collection in EDTA or citrate tubes did not affect the levels of
miR-1, miR-21, and miR-29b. They also found that, for sample storage at −80◦C, repeat freeze–thaw
cycles led to changes in miRNA levels. Although interpretation of changes in miRNA levels may not
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have been affected as long as a consistent methodology was applied to minimise variation, there is still
uncertainty about how levels are affected by blood collection tube type or anticoagulant exposure.
3.1.3. Methods of Quantifying miRNA
A major limitation of many studies stems from variations and lack of consensus for quantifying
miRNA levels. Some studies utilised controls to normalise miRNA levels such as cDNA and synthetic
Locked Nucleic Acid (LNA) (Cortez-Dias et al. [22]); others adjusted levels to various endogenous
miRNAs [13,19,23] or utilised pooled samples [24]. Unfortunately, there are no validated internal
controls such as a native miRNA level within samples, and most studies did not use a staged spike in
nonhuman miRNA, a repeat sample, or a duplicate sample at two positions on the same array to avoid
measurement bias. Thus, standardised quantification and dilution of samples in a meaningful manner
is limited.
Furthermore, many studies had an underlying rationale for quantifying certain miRNAs, such as
to verify those found to be significantly different between healthy and patient populations in previous
studies or those known to be cardiomyocyte enriched. Given that the exact mechanisms of these
miRNAs are not yet elucidated, currently studied miRNAs may simply reflect existing cardiovascular
prognostic markers and, thus, overlook those with independent prognostic utility.
Few studies investigating for prognosis utilised a pilot study to determine what miRNAs could
potentially be of use. Pilbrow et al. [19] was one such study, where a 375-miRNA panel was used to screen
35 ACS patients and 16 controls before those that were markedly different between the population were
verified in a subsequent study of 200 patients and 100 healthy controls. In this case, downregulation of
miR-652 and upregulation of miR-323-3p levels were found to add predictive power for cardiac death
or heart failure to biomarkers of left ventricular ejection fraction (LVEF) and NT-proBNP. Unfortunately,
no other study has subsequently investigated these miRNAs. Tang et al. [24] also performed a pilot
study in 115 CAD patients to determine plasma miRNAs associated with clopidogrel antiplatelet
efficacy using high-throughput illumina sequencing followed by qRT-PCR validation. These miRNAs
were then assessed in a validation cohort of 1230 CAD patients to determine prediction of major
adverse cardiovascular events (MACE) over a 3-year follow-up period.
3.1.4. Population-Based Confounders
Few studies disclosed detailed information about the patient population. As such, the potential
for phenotypic differences complicating statistical analysis may need to be considered. There is also a
lack of subgroup analyses or adjustment for differences in treatment regimes, traditional vascular risk
factor status, or medical comorbidities and a lack of matched controls. However, given the complexity
of post-ACS risk and the small sample sizes of these studies, an attempt to adjust for all population
differences and subgroup analysis may be underpowered for detecting significant differences in miRNA
expression. However, the documentation of significant between-group differences is pertinent when
such differences have been previously shown to alter miRNA expression. Such an example is in the
use of antiplatelet and anticoagulant therapies in ACS patients, which are known to alter miRNA
expression [24–26]. Moreover, few studies in this review assessing post AMI prognosis commented on
antiplatelet use [24] prior to blood sampling, which, in turn, could result in significant confounding in
reported miRNA expression.
3.2. Use of a Control Population
For those studies that had a control population, healthy controls were mostly used. This is
potentially problematic as population characteristics, including demographics, presence of CV risk
factors, or previous history of vascular disease may drive miRNA-level differences between groups
rather than the clinical presentation. With the exceptions of Alavi-Moghaddam et al., Lin et al. [13,14],
and Grabmaier et al. [12], where controls were age and sex matched, and of Grabmaier et al. [12],
where controls were also risk-factor matched, most studies did not have matched controls. However,
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most studies without a control population compared those with adverse outcomes to those without
adverse outcomes within a cohort of ACS patients. This may be a better study format for prognostic
assessment as this allows for direct comparison within the post-ACS population in a real-world setting
where prognostication is particularly important.
3.3. Prospective Studies in a Healthy Population
There are 2 prospective studies evaluating the utility of miRNAs in predicting or determining
risk of ACS in a healthy population. Both studies had a follow-up period of 10 years and used a PCR
panel to screen for differential miRNA expression at baseline, unlike the majority of the prospective
post-AMI studies, which preselected miRNA in a biased approach.
The Nord-TrØndelag Health Study (the HUNT Study) [27,28] studied healthy individuals of
which half had an MI and half did not over a 10-year follow-up period. The population was matched
for cardiovascular risk factors such as their BMI, lifestyle, and socioeconomic background. In this
cohort population, a panel of miR-106a-5p, miR-424-5p, let-7g-5p, miR-144-3p, and miR-660-5p
added predictive value to the Framingham Risk Score (FRS) [27], and subsequent investigation
found miRNA-21-5p, -26a-5p, -29c-3p, -144-3p, and -151a-5 [28] to add predictive value to the
FRS. However, the use of miRNAs with other currently used stratification tools was not evaluated.
The importance of using aged-matched controls is again highlighted in this cohort as miR-106a is
known to negatively correlate with age [29]. Therefore, future studies should incorporate the use of
age, gender, and smoking-matched controls [3]. The second prospective study in a healthy population
was the Bruneck Study [30] of 820 persons. Higher miR-126 and lower miR-223 and miR-197 levels
were found in those patients who had an AMI within the follow-up period. Again, this larger study did
not evaluate the utility of miRNAs alongside existing tools. Moreover, the importance of confounding
results with medication use is again highlighted as these miRNAs are expressed in platelets and,
therefore, affected by anti-platelet agents.
3.4. Study Limitations
This systematic review was performed by two authors only, although conducted independently.
No meta-analysis of the literature was feasible due to heterogeneity of data. Restriction of the
methodology to English language and a predominant Caucasian population resulting in study selection
bias was a further limitation.
Most studies reported varied miRNA in risk prediction post-ACS. However, three studies reported
miR-150 as a marker of risk prediction in ACS patients, showing prediction of CV death, left ventricular
(LV) remodelling, and LV impairment [14,16,31,32]. MiR-208b was also assessed in three predictive
models showing prediction of MACE over NT-proBNP and clinical syntax score in a cohort of AMI
patients over a 3-year follow-up [33] and was superior to NT-proBNP in predicting LV remodelling [34]
as well as in predicting mortality post AMI at 6 months [13]. MiR-208b has been shown to be
upregulated in AMI patients, released immediately post PCI, and produced in rat myocardium as a
marker of myocardial injury [13] and is upregulated in the myocardium of dilated cardiomyopathy
patients [35], supporting its expression as representative of human cardiomyocyte growth/death.
It is important to note that most studies did not utilise a validated risk scoring system or a
comprehensive panel of cardiovascular risk factors. For example, isolated findings lost significance
after adjusting for common cardiovascular risk factors (e.g., Widera, et al. [36] and Eitel, et al. [37]).
In contrast, some risk prediction models of outcome based on clinical variables and traditional
biomarkers were improved with miRNA, such as miR-208b and -34a [34] and miR-150 [16] in LV
function and size. These data point to a role of certain miRNA to improve risk prediction alongside
traditional biomarkers and clinical risk predictors in ACS patients.
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3.5. Future Studies
Future studies looking at miRNA as prognostic markers in ACS should be a minimum of 12
months in duration and ideally longer follow-up to adequately assess CV morbidity such as stent
restenosis, bleeding, ischaemic events, and heart failure as well as mortality with combined and
well-defined endpoints [38]. They should have an unbiased approach to miRNA selection and stringent
quality checks during sample processing and miRNA measurements, such as staged nonhuman spike
in miRNA and duplicate and repeat sampling on arrays to avoid measurement bias [39]. They should
account for known confounders including CV risk factors and medications. Moreover, they should
have low level of bias and adequate sample size to detect differences in a heterogenous population.
Another important consideration is ensuring reproducibility in data by using discovery and validation
cohorts. Such an approach will help in identifying significantly dysregulated microRNAs in a discovery
cohort followed by confirmation of these findings in a separate, bigger validation cohort.
Few studies assessed in this review came close to achieving these goals. Several studies had
reasonable follow-up times of at least 12 months [12,14,15,17,19,22,24,33,34,40–48], and of those, most
had reasonable sample size except for Liu et al. [44], Jantti et al. [43], Matsumoto et al. [46], and
Costa et al. [40]. Low level of bias was reported across all domains in five of these studies with adequate
follow-up and reasonable sample size, including studies by Lv et al., Pilbrow et al., Schulte et al.,
Mayer et al., and Tang et al. [15,19,24,34,48]. Of these 5 studies, all but 2 utilised previous literature
search for miRNA selection. Given this relatively new field with a lack of knowledge of biological
mechanisms of miRNA to date, this is limiting in its interpretation of miRNA as prognostic markers
in ACS, although not taking away from the studies on which these selections were based [30,49–52].
It is important in this developing field to utilise an unbiased approach to investigation of miRNA
as undertaken by Tang et al. and Pilbrow et al. Pilbrow et al. did not assess MACE but did assess
readmission for heart failure and mortality as prognostic outcomes in ACS, a limitation in this study.
Tang et al. utilised a discovery and validation approach and assessed MACE in ACS patients. However,
this was only assessed for 6 candidate miRNAs associated with clopidogrel antiplatelet efficacy and,
thus, quite a specific group of miRNAs for prediction of MACE in an ACS population.
4. Conclusions
Taken together, our findings do not support the use of miRNA for prognostication post-ACS
beyond traditional cardiovascular risk factors, existing risk scores, and stratifications tools currently.
The main barriers include small sample sizes, bias selection of miRNAs already known to be implicated
in cardiovascular disease, and inadequate efforts to ensure data reproducibility. Future studies will need
to be considerably larger with longer follow-up times beyond 12 months, to incorporate the efficient use
of screening panels to detect differences in miRNAs of unknown significance, and to allow for a more
comprehensive assessment of potential confounders and well-defined outcomes including ischaemia,
restenosis, bleeding events, and heart failure alongside mortality. Moreover, greater consistency in
methodology, reporting of population selection, patient characteristics, and statistical consideration of
comorbid factors and potential confounders is required to clearly determine whether miRNAs have
prognostic utility in this setting.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/8/12/1572/s1,
Figure S1: Number of studies investigating each miRNA, Table S1: Study characteristics, Table S2: QUIPS risk of
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